Arrowhead Pharmaceuticals Inc. (Nasdaq: ARWR) will discontinue development of clinical stage drug candidates ARC-520, ARC-521 and ARC-AAT sending the stock price plummeting $2.95 to close at $1.44.
Arrowhead Pharmaceuticals discontinues drug development
November 30, 2016 at 16:41 PM EST
